Liver cancer study after surgery or pre-surgery therapy
Part of Cancer, Digestive system clinical trials.
This study looks at genetic markers in the blood of people with liver cancer who are having surgery, either right away or after some treatment first. It aims to find out why some patients do better, which could help personalize care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (HCC) for the first time.
- You are scheduled for surgery to remove the cancer, which might be after some other treatment.
- Your doctor can get a tissue sample and you have detectable tumor DNA in your blood before starting.
- Your liver cancer is not from another cancer or a type called cholangiocarcinoma.
- You do not have another active cancer at the same time.
- You have not had an organ transplant or a condition called hepatic encephalopathy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
This trial uses a simple blood test to check for signs of liver cancer coming back after surgery. It may help doctors catch a return earlier and guide further treatment.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This study uses digital scans of your tumor tissue and CT/MRI images to build a computer model that helps predict whether you might need extra treatment (adjuvant therapy) after liver cancer surgery. The goal is to use your own tissue and scan data to personalize follow-up care.
This trial uses a test on your tumor (an 'organoid') to pick which medicines might work best for you after surgery. The goal is to lower the chance of your liver cancer coming back.
This study uses a simple blood test to monitor tiny pieces of tumor DNA (ctDNA) in people with colorectal cancer that spread to the liver or with liver cancer (HCC), before and after liver surgery or transplant. It aims to help doctors detect cancer return earlier and guide treatment.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.